SA
PDLI

SRH Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

SRH Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,300
Closed -$41K – 282
2018
Q4 		$41K Hold
14,300
– – 0.16% 86
2018
Q3 		$38K Hold
14,300
– – 0.13% 97
2018
Q2 		$33K Buy
+14,300
New +$39.9K 0.12% 102

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SRH Advisors's PDLI Position: Q1 2019 in Review

SRH Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 14,300 shares — an estimated $41K sold.

SRH Advisors first reported a position in PDLI in Q2 2018 and held it in 3 quarters. The position peaked at $41K in Q4 2018. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

  • SRH Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
  • SRH Advisors sold 14,300 PDL BioPharma, Inc. shares in Q1 2019, an estimated $41K.
  • SRH Advisors first reported a position in PDL BioPharma, Inc. in Q2 2018 and held it in 3 quarters.
  • SRH Advisors's PDL BioPharma, Inc. position peaked at $41K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on SRH Advisors's 13F filing for Q1 2019, filed 25 Apr 2019.